Company: ARVN
Filing Date: 2025-08-08
Form Type: 8-K
Source: 0001655759-25-000141
Chunk: 1

Company: ARVINAS, INC.
Filing Date: 2025-08-08
Form: 8-K
Item: Item 8.01
Chunk 1
---
Item 8.01 Other Events.

On August 8, 2025, Arvinas, Inc. issued a press release announcing that the FDA has accepted the NDA for vepdegestrant for the treatment of patients with ER+/HER2- ESR1-mutated advanced or metastatic breast cancer who have previously received endocrine-based therapy. The FDA has assigned a Prescription Drug User Fee Act action date of June 5, 2026.

Item 9.01 Financial Statements and Exhibits.